Munnell E R, Dilling E, Grantham R N, Harkey M R, Mohr J A
Ann Thorac Surg. 1978 Apr;25(4):289-97. doi: 10.1016/s0003-4975(10)63543-6.
Twelve patients with solitary bronchiolar carcinoma had lobectomy and were followed for up to 16 years. The concept of a multicentric origin of bronchiolar carcinoma, maintained for more than eight decades, should be discarded. The neoplasm arises indolently and usually in an area of pulmonary fibrosis. After lobectomy patients can now expect to follow one of four courses: (1) to be alive and well without recurrence; (2) after several years to have pulmonary recurrence or a new carcinoma; (3) with minute spread at the time of lobectomy to have metastasis develop in a short period; or (4) to die of unrelated conditions. The overall 5-year survival with this tumor is about 75%. Late recurrence or the development of another primary tumor, however, prompts the need for prolonged follow-up. Immunologically, patients have circulating antibodies when well and demonstrable circulating antigens with recurrence. The survival rate of selected patients with solitary bronchiolar carcinoma (eliminating those patients with microscopic spread from the primary neoplasm at the time of resection and those dying of other causes) was 100% after 5 years and 75% after 10 years.
12例孤立性细支气管癌患者接受了肺叶切除术，并随访长达16年。细支气管癌多中心起源的概念已维持了八十多年，现在应该摒弃。肿瘤生长缓慢，通常发生在肺纤维化区域。肺叶切除术后，患者现在可能会经历以下四种病程之一：（1）存活且无复发；（2）数年后出现肺部复发或新发癌；（3）在肺叶切除时已有微小播散，短期内发生转移；或（4）死于无关疾病。该肿瘤的总体5年生存率约为75%。然而，晚期复发或另一个原发性肿瘤的发生，促使需要进行长期随访。在免疫学方面，患者病情良好时具有循环抗体，复发时可检测到循环抗原。部分孤立性细支气管癌患者（排除那些在切除时已有原发性肿瘤微小播散的患者以及死于其他原因的患者）的生存率在5年后为100%，10年后为75%。
